Skip to main content
James Seibold, MD, Rheumatology, Aiken, SC

JamesRSeiboldMD

Rheumatology Aiken, SC

Scleroderma & Related

President, Scleroderma Research Consultants LLC

Dr. Seibold is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Seibold's full profile

Already have an account?

Education & Training

  • UPMC Medical Education
    UPMC Medical EducationFellowship, Rheumatology, 1978 - 1980
  • Zucker School of Medicine at Hofstra/Northwell
    Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1975 - 1978
  • Stony Brook University Health Sciences Center School of Medicine
    Stony Brook University Health Sciences Center School of MedicineClass of 1975
  • Louisiana State University
    Louisiana State UniversityB.S., 1969 - 1972

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 2010 - 2025
  • MI State Medical License
    MI State Medical License Active through 2014
  • NY State Medical License
    NY State Medical License Active through 2012
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • Cited in "Best Doctors in Connecticut" 2010
  • Cited in "Best Doctors in Metropolitan Detroit Area" 2005
  • International Health Worker of the Year Cambridge Biographical Society, 2004
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Progress and priorities in systemic sclerosis: the next ten years-report from the World Scleroderma Foundation  
    Furst DE, Pope JE, Seibold JR, Bombardieri S, Denton CP, Distler O, Kahaleh B, Kennedy AT, Khanna D, Lafyatis R, Tyndall AD, Matucci-Cerinic M, J Scleroderma Rel Disorders, 1/1/2016
  • The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis  
    Khanna D, Berrocal VJ, Giannini E, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen VD, Assassi S, Schiopu E, Phillips K, Simms R, Allanore Y, Denton CP, D..., Arthritis Rheum, Arthritis Care Res, 1/1/2016
  • Connective Tissue Disease Related Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis: Provisional Core-Sets of Domains and Instruments for Use in Clinical Tr...  
    Saketkoo LA, Mittoo S, Huscher D, Dellaripa PF, Distler O, Flaherty K, Frankel S, Khanna D, Oddis CV, Denton CP , Fischer A, Kowal-Bielecka OM, LeSage D, Merkel P, Phi..., Thorax, 1/20/2014
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Safety and tolerability of pirfenidone in patients with systemic sclerosis-associated interstitial lung disease-the LOTUSS Study.
    Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Schiopu E, Chen D, Gorina E, Tagliaferri M, Seibold JR, Arthritis Rheum, ATS, EULAR, ERS and ACR, 1/1/2015
  • Development of a combined response index for clinical trials in early diffuse systemic sclerosis-the CRISS index.
    Khanna D, Berrocal V, Giannini E, Mayes M. Merkel P, Seibold J, Baron M, Clements P, Steen V, Lovell D, Siegel J, Distler O, Allanore Y, Czirjak L, Denton CP, Johnson ..., Arthritis Rheum, 1/1/2014
  • Developing a disease activity and therapeutic response index in connective tissue disease related interstitial lung disease: initial results of a Delphi exercise.
    Saketkoo L, Huscher D, Khanna D, Dellaripa P, Flaherty K, Matteson EL, Oddis CV, Phillips K, Wells A, Denton CP, Distler O, Kowal-Bielecka O, Pittrow D, Strand V, Brow..., Ann Rheum Dis, 1/1/2013
  • Join now to see all

Lectures

  • "Emerging Therapies" 
    Lisbon, Portugal - 1/1/2016
  • "Advancing Potential Drugs to Patient Care"-Trial Design and Outcome measures 
    1/1/2015
  • "The challenge of clinical trials in scleroderma" 
    Cambridge, UK - 1/1/2015
  • Join now to see all

Other

  • Raynaud Phenomenon-A Guide to Pathogenesis and Treatment 
    Khanna D, Gladue H, Seibold JR
    1/1/2014
  • Module 9 Management-Vasodilators. 
    Riemekasten G, Seibold JR, EUSTAR Online Course in Systemic Sclerosis
    http://www.eular-ssc-onlinecourse.org/
    1/1/2012
  • Module 1-Pathogenesis-An Overview. 
    Distler O, Denton CP, Seibold JR, EUSTAR Online Course in Systemic Sclerosis
    http://www.eular-ssc-onlinecourse.org/
    1/1/2012
  • Join now to see all

Press Mentions

  • Scleroderma Two Year Data to Be Presented at the 4th Systemic Sclerosis World Congress
    Scleroderma Two Year Data to Be Presented at the 4th Systemic Sclerosis World CongressFebruary 10th, 2016
  • Scleroderma Two Year Data to Be Presented at the 4
    Scleroderma Two Year Data to Be Presented at the 4February 10th, 2016
  • Scleroderma Two Year Data to Be Presented at the 4
    Scleroderma Two Year Data to Be Presented at the 4February 10th, 2016
  • Join now to see all

Grant Support

  • Trial Of Intravenous Rituximab In Treatment Of Refractory MyositisNational Center For Research Resources2007
  • Scleroderma Cyclophosphamide Or Transplantation (SCOT) StudyNational Center For Research Resources2007
  • High-Dose Immuntx W/ Autologous Stem Cell Rescue For Systemic SclerosisNational Center For Research Resources2006

Professional Memberships